Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• P2Y12 adenosine di-phosphate (ADP) receptor antagonists are crucial for managing thrombotic risks in acute coronary syndromes and percutaneous coronary revascularization.
• Evidence links P2Y12 inhibitor on-treatment platelet reactivity to thrombotic event rates.
• Excessive platelet inhibition has been associated with increased bleeding events.

Purpose of the Study:

• To review the evidence supporting a therapeutic window for P2Y12-ADP receptor antagonists.
• To explore the potential of monitoring platelet reactivity for optimizing antiplatelet therapy.
• To enhance clinical outcomes in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.

Main Methods:

• Literature review of studies investigating P2Y12 receptor antagonists.
• Analysis of data correlating platelet reactivity with thrombotic and bleeding events.
• Synthesis of evidence regarding therapeutic windows and monitoring strategies.

Main Results:

• A correlation exists between platelet reactivity inhibition levels and thrombotic recurrence.
• Excessive platelet inhibition is linked to an increased risk of bleeding.
• These findings suggest a potential therapeutic window for P2Y12 inhibitors.

Conclusions:

• Platelet reactivity monitoring offers a potential strategy to personalize antiplatelet therapy.
• Optimizing P2Y12 inhibitor therapy can help prevent thrombotic events while minimizing bleeding complications.
• Individualized antiplatelet therapy guided by platelet reactivity measurement may improve patient outcomes.